HUTCHMED (NASDAQ:HCM) Shares Gap Up – Should You Buy?

HUTCHMED (China) Limited (NASDAQ:HCM)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $13.72, but opened at $14.36. HUTCHMED shares last traded at $14.60, with a volume of 11,033 shares trading hands.

Analyst Ratings Changes

Separately, StockNews.com lowered shares of HUTCHMED from a “buy” rating to a “hold” rating in a research note on Monday, November 18th.

HUTCHMED Trading Up 7.1 %

The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. The stock’s 50 day moving average is $14.32 and its 200 day moving average is $16.95.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in HCM. Public Employees Retirement System of Ohio acquired a new position in shares of HUTCHMED during the third quarter valued at approximately $35,000. Barclays PLC increased its stake in shares of HUTCHMED by 1,483.6% during the fourth quarter. Barclays PLC now owns 2,407 shares of the company’s stock valued at $35,000 after acquiring an additional 2,255 shares during the period. Blue Trust Inc. increased its stake in shares of HUTCHMED by 638.2% during the third quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock valued at $69,000 after acquiring an additional 3,057 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of HUTCHMED by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company’s stock valued at $117,000 after acquiring an additional 2,321 shares during the period. Finally, Summit Trail Advisors LLC boosted its holdings in HUTCHMED by 14.4% during the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company’s stock worth $189,000 after buying an additional 1,647 shares in the last quarter. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.